Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sarepta Therapeutics stock in Canada | $73.05

Own Sarepta Therapeutics shares in just a few minutes.

Sarepta Therapeutics, Inc
+$0.39 (+0.56%)

Sarepta Therapeutics (SRPT) is a leading biotechnology business based in the US. It opened the day at $73.01 after a previous close of $72.94. During the day the price has varied from a low of $71.818 to a high of $73.18. The latest price was $73.05 (25 minute delay). Sarepta Therapeutics is listed on the NASDAQ and employs 866 staff. All prices are listed in US Dollars.

How to buy Sarepta Therapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SRPT in this case.
  5. Research Sarepta Therapeutics stocks. The platform should provide the latest information available.
  6. Buy your Sarepta Therapeutics stocks. It's that simple.

How has Coronavirus impacted Sarepta Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Sarepta Therapeutics's stock price has had significant negative movement.

Its last market close was $75.65, which is 38.98% down on its pre-crash value of $123.98 and 3.19% down on the lowest point reached during the March crash when the stocks fell as low as $78.06.

If you had bought $1,000 worth of Sarepta Therapeutics stocks at the start of February 2020, those stocks would have been worth $774.92 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $655.89.

Sarepta Therapeutics stock price

Use our graph to track the performance of SRPT stocks over time.

Sarepta Therapeutics stocks at a glance

Information last updated 2021-07-09.
Previous close$72.94
Change $0.11
Change % 0.1508%
Volume 303,348
Information last updated 2021-07-28.
52-week range$65.3 - $181.83
50-day moving average $75.4143
200-day moving average $79.688
Wall St. target price$125.82
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.135

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available Asset Types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Get up to 50 free trades. Be one of the first 100 new Qtrade clients to use the promo code 50FREETRADES and deposit a minimum of $10,000 (or top up to $15,000 to get $150 transfer fees waived). Valid until September 30, 2021.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Sarepta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sarepta Therapeutics price performance over time

Historical closes compared with the last close of $73.05

1 month (2021-07-02) -2.91%
3 months (2021-05-03) -5.27%

Is Sarepta Therapeutics under- or over-valued?

Valuing Sarepta Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sarepta Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sarepta Therapeutics's PEG ratio

Sarepta Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 159.25. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Sarepta Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Sarepta Therapeutics financials

Revenue TTM USD$573.4 million
Gross profit TTM USD$-245,526,000
Return on assets TTM -12.86%
Return on equity TTM -83.78%
Profit margin -122.77%
Book value $6.714
Market capitalisation USD$5.4 billion

TTM: trailing 12 months

How to short and sell Sarepta Therapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SRPT.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 6.5 million Sarepta Therapeutics stocks held short by investors – that's known as Sarepta Therapeutics's "short interest". This figure is 0.9% up from 6.4 million last month.

There are a few different ways that this level of interest in shorting Sarepta Therapeutics stocks can be evaluated.

Sarepta Therapeutics's "short interest ratio" (SIR)

Sarepta Therapeutics's "short interest ratio" (SIR) is the quantity of Sarepta Therapeutics stocks currently shorted divided by the average quantity of Sarepta Therapeutics stocks traded daily (recently around 800737.85450062). Sarepta Therapeutics's SIR currently stands at 8.11. In other words for every 100,000 Sarepta Therapeutics stocks traded daily on the market, roughly 8110 stocks are currently held short.

However Sarepta Therapeutics's short interest can also be evaluated against the total number of Sarepta Therapeutics stocks, or, against the total number of tradable Sarepta Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sarepta Therapeutics's short interest could be expressed as 0.08% of the outstanding stocks (for every 100,000 Sarepta Therapeutics stocks in existence, roughly 80 stocks are currently held short) or 0.0854% of the tradable stocks (for every 100,000 tradable Sarepta Therapeutics stocks, roughly 85 stocks are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the stock price, with fewer people currently willing to bet against Sarepta Therapeutics.

Find out more about how you can short Sarepta Therapeutics stock.

Sarepta Therapeutics stock dividends

We're not expecting Sarepta Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Have Sarepta Therapeutics stocks ever split?

Sarepta Therapeutics stocks were split on a 1:6 basis on 12 July 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sarepta Therapeutics stocks – just the quantity. However, indirectly, the new 500% higher stock price could have impacted the market appetite for Sarepta Therapeutics stocks which in turn could have impacted Sarepta Therapeutics's stock price.

Sarepta Therapeutics stock price volatility

Over the last 12 months, Sarepta Therapeutics's stocks have ranged in value from as little as $65.3 up to $181.83. A popular way to gauge a stock's volatility is its "beta".

SRPT.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sarepta Therapeutics's is 1.4358. This would suggest that Sarepta Therapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sarepta Therapeutics overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Stocks similar to Sarepta Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site